Since the development of anti-HER2 therapy, outcomes for HER2-positive patients have improved significantly.9,10 The accurate identification of HER2 status and initiation of disease-specific therapy can decrease the risk of death and alter the prognosis of a patient who has HER2-positive breast cancer.9 HER2 status is assessed in all newly diagnosed, invasive, or recurrent breast tumors. The gene discussed is ERBB2; the disease is breast cancer.